Floatz logo

(+)-VINCRISTINE

Microsatellite Instability-High Solid Malignant Tumor

Neonc Technologies, Inc.Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Microsatellite Instability-High Solid Malignant Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Pembrolizumab
Neonc Technologies, Inc.
Phase 2B
Rosiglitazone
Dan Zandberg
Phase 2CCC
Letrozole
Dan Zandberg
Phase 2CCC
Metformin
Dan Zandberg
Phase 2CCC

View all 14 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →